TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Kalaris Therapeutics ( (KLRS) ) just unveiled an announcement.
At the 2025 Annual Meeting of Stockholders held on August 12, 2025, Kalaris Therapeutics, Inc. announced the election of Srinivas Akkaraju, M.D., Ph.D., and Andrew Oxtoby as Class II directors for a three-year term ending in 2028. Additionally, the stockholders ratified Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
The most recent analyst rating on (KLRS) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Kalaris Therapeutics stock, see the KLRS Stock Forecast page.
Spark’s Take on KLRS Stock
According to Spark, TipRanks’ AI Analyst, KLRS is a Underperform.
AlloVir’s stock is heavily impacted by its financial performance challenges, including consistent net losses and negative cash flow. Technical analysis also indicates a bearish trend, with prices below key moving averages and weak momentum indicators. The negative P/E ratio and absence of dividend yield further highlight valuation concerns, making it a less attractive investment at this time.
To see Spark’s full report on KLRS stock, click here.
More about Kalaris Therapeutics
Average Trading Volume: 49,524
Technical Sentiment Signal: Sell
Current Market Cap: $41.68M
For an in-depth examination of KLRS stock, go to TipRanks’ Overview page.